Welcome to our dedicated page for ZimVie news (Ticker: $ZIMV), a resource for investors and traders seeking the latest updates and insights on ZimVie stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZimVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZimVie's position in the market.
On May 16, 2024, ZimVie, a global leader in the dental market, announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Jaws & Paws Conference on May 30, 2024, at 11:30 a.m. Eastern Time, and at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties can access a live webcast of these presentations through the 'Investors' section on ZimVie's website.
ZimVie Inc. (Nasdaq: ZIMV) reported third party net sales of $118.2 million, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million for the first quarter of 2024. The company completed the sale of its spine business for $375 million, repaid $275 million of debt, and is now focusing on its dental market leadership.